Canaccord Genuity adjusted its outlook on Akero Therapeutics (NASDAQ: NASDAQ:AKRO) shares, raising the price target to $73 ...

Canaccord Genuity analyst Owen Humphries maintained a Buy rating on Kogan.com Ltd. (KGGNF – Research Report) on January 24 and set a price ...

Canaccord Genuity analyst Warren Jeffries maintained a Buy rating on BSA Limited (BSA – Research Report) on January 24 and set a price target ...

Canaccord Genuity updated its outlook on Stride Inc. (NYSE:LRN), increasing the price target to $130 from the previous $100, ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 0.82% of ...

Mining fundamentals are strong with the cost to mine around $27K per bitcoin (BTC) for the larger players, the report said.

Vertical Aerospace (NYSE:EVTL – Free Report) had its price target cut by Canaccord Genuity Group from $16.00 to $13.50 in a report issued on Friday,Benzinga reports. They currently have a buy rating ...

Analysts at Canaccord Genuity slightly raised their target price on exploration and development firm Greatland Gold from ...

Analysts at Canaccord Genuity initiated coverage on sales and marketing technology group Bango with a 'buy' rating and a ...

Canaccord Genuity raised its price target on Tesla (TSLA) to $404 per share from $298, citing optimism over the company’s growth, including in its energy business and possible robotics venture.

Canaccord downgraded Inari Medical (NARI) to Hold from Buy with a price target of $80, up from $74, after Stryker (SYK) entered into a definitive agreement to acquire Inari in cash for $80 per share.

Please ask to participate in the Canaccord Genuity Group Inc. Q3/25 results call. If a conference call ID is requested, please use 04356. A replay of the conference call will be made available ...